Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 3
2005 1
2006 4
2007 7
2008 6
2009 3
2010 6
2011 7
2012 9
2013 6
2014 8
2015 11
2016 18
2017 9
2018 24
2019 35
2020 24
2021 46
2022 45
2023 39
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Taki M, et al. Among authors: mandai m. Clin Cancer Res. 2021 Sep 1;27(17):4669-4679. doi: 10.1158/1078-0432.CCR-20-4459. Epub 2021 Apr 7. Clin Cancer Res. 2021. PMID: 33827891 Review.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Evolutionary histories of breast cancer and related clones.
Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, Chigusa Y, Kawai M, Sawada M, Inoue T, Takeuchi Y, Maeda H, Baba S, Shiozawa Y, Saiki R, Nakagawa MM, Nannya Y, Ochi Y, Hirano T, Nakagawa T, Inagaki-Kawata Y, Aoki K, Hirata M, Nanki K, Matano M, Saito M, Suzuki E, Takada M, Kawashima M, Kawaguchi K, Chiba K, Shiraishi Y, Takita J, Miyano S, Mandai M, Sato T, Takeuchi K, Haga H, Toi M, Ogawa S. Nishimura T, et al. Among authors: mandai m. Nature. 2023 Aug;620(7974):607-614. doi: 10.1038/s41586-023-06333-9. Epub 2023 Jul 26. Nature. 2023. PMID: 37495687 Free PMC article.
Capturing human trophoblast development with naive pluripotent stem cells in vitro.
Io S, Kabata M, Iemura Y, Semi K, Morone N, Minagawa A, Wang B, Okamoto I, Nakamura T, Kojima Y, Iwatani C, Tsuchiya H, Kaswandy B, Kondoh E, Kaneko S, Woltjen K, Saitou M, Yamamoto T, Mandai M, Takashima Y. Io S, et al. Among authors: mandai m. Cell Stem Cell. 2021 Jun 3;28(6):1023-1039.e13. doi: 10.1016/j.stem.2021.03.013. Epub 2021 Apr 7. Cell Stem Cell. 2021. PMID: 33831365 Free article.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, Suzuki H, Hosoe Y, Furutake Y, Taki M, Abiko K, Yamaguchi K, Nakai H, Baba T, Matsumura N, Yoshizawa A, Ueno H, Mandai M. Ukita M, et al. Among authors: mandai m. JCI Insight. 2022 Jun 22;7(12):e157215. doi: 10.1172/jci.insight.157215. JCI Insight. 2022. PMID: 35552285 Free PMC article.
Pregnancy Epulis.
Chigusa Y, Okuda R, Teratani Y, Matsuzaka S, Mandai M. Chigusa Y, et al. Among authors: mandai m. JMA J. 2023 Apr 14;6(2):206-208. doi: 10.31662/jmaj.2022-0156. Epub 2023 Feb 27. JMA J. 2023. PMID: 37179727 Free PMC article. No abstract available.
B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, Takamatsu S, Mise Y, Ukita M, Taki M, Yamanoi K, Horikawa N, Abiko K, Yamaguchi K, Baba T, Matsumura N, Mandai M. Miyamoto T, et al. Among authors: mandai m. Cancer Immunol Res. 2022 Jan;10(1):56-69. doi: 10.1158/2326-6066.CIR-21-0407. Epub 2021 Nov 19. Cancer Immunol Res. 2022. PMID: 34799346 Free PMC article.
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Hamanishi J, et al. Among authors: mandai m. J Clin Oncol. 2021 Nov 20;39(33):3671-3681. doi: 10.1200/JCO.21.00334. Epub 2021 Sep 2. J Clin Oncol. 2021. PMID: 34473544 Free PMC article. Clinical Trial.
278 results